REV-ERB is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-06. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
An additional study published in 2020 by Woodward and colleagues, for the journal Science Advances indicates that during their growth from juvenile to adult, Tyrannosaurus was capable of slowing down its growth to counter environmental factors such as lack of food. Based on BMRP 2002.4.1 and BMRP 2006.4.4 between 13 and 15 years old housed at the Burpee Museum in Illinois then referred to as juvenile Tyrannosaurus specimens, the authors suggested that the rate of maturation for Tyrannosaurus was dependent on resource abundance. This study also indicates that in such changing environments, Tyrannosaurus was particularly well-suited to an environment that shifted yearly in regards to resource abundance, hinting that other midsize predators might have had difficulty surviving in such harsh conditions and explaining the niche partitioning between juvenile and adult tyrannosaurs. The study further suggested that Tyrannosaurus and Nanotyrannus are synonymous, due to analysis of the growth rings in the bones of the two specimens studied. In January 2026, Woodward, Myhrvold and Horner performed a comprehensive histological analysis of 17 tyrannosaur specimens, and argued that Tyrannosaurus likely experienced a more gradual annual growth rate slope than indicated by earlier studies and evidence of a protracted subadult stage, reaching asymptotic size at around 35–40 years of age. The upper limit of the annual growth rate estimate is approximately 43–53 years.
==== Broad-spectrum antibiotics ==== This group of antibiotics is called "broad-spectrum" because they are active against a wide range of Gram-negative bacteria such as Escherichia coli and Salmonella typhi, for which penicillin is not suitable. However, resistance in these organisms is now common.
Duterte campaigned for decentralization and a shift to a federal government during the 2016 presidential election. In an October 2014 forum organized by Federal Movement for a Better Philippines in Cebu City prior to joining the presidential race, the then-mayor of Davao City called for the creation of two federal states for Moro people as a solution to the problems besetting Mindanao. Mayor Duterte said that Nur Misuari and his Moro National Liberation Front do not see eye-to-eye with the Moro Islamic Liberation Front which the administration of President Benigno Aquino III had inked a peace deal with. He also said that the "template of the Bangsamoro Basic Law is federal", but what is granted to the Bangsamoro should also be granted to other Moro groups and other regions in the country. In a dialogue with the Makati Business Club prior to the elections, Duterte said he is open to "toning down the Constitution" to accommodate more foreign investors to the Philippines. He also said he is open to up to 70 percent foreign ownership of businesses in the country and foreign lease of lands up to 60 years, but will "leave it to Congress to decide".
Sources: en.wikipedia.org
=== Structural relationships === Much reference has been made in the literature (both lay and professional) of the structural kinship of synephrine with ephedrine, or with phenylephrine, often with the implication that the perceived similarities in structure should result in similarities in pharmacological properties. However, from a chemical perspective, synephrine is also related to a very large number of other drugs whose structures are based on the phenethylamine skeleton, and although some properties are common, others are not, making unqualified comparisons and generalizations inappropriate. Thus, replacement of the N-methyl group in synephrine with a hydrogen atom gives octopamine; replacement of the β-hydroxy group in synephrine by a H atom gives N-methyltyramine; replacement of the synephrine phenolic 4-OH group by a –H gives halostachine. If the synephrine phenolic 4-OH group is shifted to the meta-, or 3-position on the benzene ring, the compound known as phenylephrine (or m-synephrine, or "Neo-synephrine") results; if the same group is shifted to the ortho-, or 2-position on the ring, o-synephrine results. Addition of another phenolic –OH group to the 3-position of the benzene ring produces the neurotransmitter epinephrine; addition of a methyl group to the α-position in the side-chain of synephrine gives oxilofrine (methylsynephrine). Four stereoisomers (two pairs of enantiomers) are possible for this substance.
Also in the year 1808, at the conclusion of the Spanish reconquest of Santo Domingo and the repossession of the Eastern half of Hispaniola by Spain, the Governor General of Cuba sent all of the recent arrived refugees back to that colony. In so doing, these immigrants then dismantled their two Lodges they had been operating, Concordia and Perseverancia, and left the island. Many of these refugees moved to New Orleans, Louisiana District by 1809, and the next year, established the Concorde Lodge, No. 117, chartered under the Grand Lodge of Pennsylvania. Later in 1810, with three other Lodges in New Orleans, they established the Grand Lodge of Louisiana. Perseverancia was also reorganized in New Orleans under the name Perseverance Lodge No. 118. The only one of these Lodges that remained in Cuba was the Temple of the Theologic Virtues, and it also changed its name to Spanish; Templo de las Virtudes Teologales. The French members mostly having left the island, the remaining members were mostly Creole.
=== Lifestyle and diet === Drinking enough water may help to keep skin hydrated, especially in individuals who are chronically dehydrated. A poor diet lacking vitamins can lead to skin problems, such as scurvy, pellagra, and numerous subclinical skin pathologies that have not been studied in detail. Lack of sleep has been shown to make conditions like atopic dermatitis, eczema and psoriasis worse, and these conditions have in turn been shown to reduce sleep quality.
=== Further medieval development === The Fisher King's next development occurred around the end of the 12th century in Robert de Boron's Joseph d'Arimathie, the first work to connect the Grail with Jesus. Here, the "Rich Fisher" is called Bron, a name similar enough to Bran to suggest a relationship, and said to be the brother-in-law of Joseph of Arimathea, who had used the Grail to catch Christ's blood before laying him in the sepulchre. Joseph founds a religious community that travels eventually to Britain and entrusts the Grail to Bron (who is called the "Rich Fisher" because he catches a fish eaten at the Grail table). Bron founds the line of Grail keepers that eventually includes Perceval. The Lancelot-Grail (Vulgate) prose cycle includes a more elaborate history of the Fisher King. Many in his line are wounded for their failings, beginning with his ancestor Alain (the "Rich Fisherman"), and the only two that survived till the Grail Quest are the Maimed King, named Pellehan (Pellean, Pelleam, Pellehem), and the Fisher King, his son Pelles. The Vulgate Merlin Continuation further features besides his father, unnamed there, a brother of Pelles also named Alain, and in one variant also their brother and their cousin both named Pellinor, all featuring as Grail Kings of the Fisher and/or Maimed kind. Pelles engineers the birth of Galahad by tricking Lancelot into bed with his daughter Elaine, and it is prophesied that Galahad will achieve the Grail and heal the Wasteland and the Maimed King.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.